The Effects of CD48 MoAb Infusion on BM Lymphohematopoietic Reconstitution in Splenectomized or Nonsplenectomized Lethally Irradiated Recipients of Congenic BM Grafts
| Splenectomized . | Day . | αCD48 . | Absolute No. . | Donor . | Host . | CD19+ . | Mac1+ . |
|---|---|---|---|---|---|---|---|
| No | 7 | No | 3.8 (0.8) | 2.1 (0.4) | 1.0 (0.2) | 0.3 (0.1) | 1.9 (0.3) |
| No | 7 | Yes | 1.4 (0.2)7-150 | 0.7 (0.1)7-150 | 0.4 (0.1)7-150 | 0.1 (0.0) | 0.5 (0.1)7-151 |
| Yes | 7 | No | 3.2 (0.5) | 2.0 (0.3) | 0.8 (0.2) | 0.2 (0.1) | 1.7 (0.2) |
| Yes | 7 | Yes | 1.6 (0.2)7-150 | 0.8 (0.1)7-150 | 0.5 (0.1) | 0.1 (0.0) | 0.6 (0.1)7-151 |
| No | 10 | No | 16.7 (3.0) | 11.7 (2.2) | 4.5 (0.6) | 3.4 (0.4) | 10.1 (2.0) |
| No | 10 | Yes | 8.0 (2.2)7-150 | 4.9 (1.3)7-150 | 2.4 (1.0) | 1.1 (0.6)7-150 | 3.8 (1.0)7-150 |
| Yes | 10 | No | 17.0 (1.5) | 12.2 (1.2) | 3.7 (0.5) | 1.9 (0.2) | 11.4 (1.2) |
| Yes | 10 | Yes | 10.1 (0.6)7-151 | 6.9 (0.6)7-151 | 2.0 (0.2)7-150 | 0.7 (0.2)7-151 | 6.0 (0.8)7-151 |
| No | 14 | No | 29.2 (3.5) | 12.0 (0.9) | 16.6 (2.7) | 17.1 (3.0) | 7.5 (0.4) |
| No | 14 | Yes | 17.7 (0.4)7-150 | 8.3 (1.0)7-150 | 9.1 (1.2)7-150 | 7.6 (2.4)7-150 | 5.3 (1.6) |
| Yes | 14 | No | 36.4 (2.4) | 16.4 (2.4) | 18.9 (1.4) | 17.1 (0.8) | 11.2 (2.0) |
| Yes | 14 | Yes | 22.2 (2.4)7-151 | 10.4 (2.0) | 10.9 (0.6)7-151 | 6.0 (0.4)7-151 | 8.1 (2.0) |
| Splenectomized . | Day . | αCD48 . | Absolute No. . | Donor . | Host . | CD19+ . | Mac1+ . |
|---|---|---|---|---|---|---|---|
| No | 7 | No | 3.8 (0.8) | 2.1 (0.4) | 1.0 (0.2) | 0.3 (0.1) | 1.9 (0.3) |
| No | 7 | Yes | 1.4 (0.2)7-150 | 0.7 (0.1)7-150 | 0.4 (0.1)7-150 | 0.1 (0.0) | 0.5 (0.1)7-151 |
| Yes | 7 | No | 3.2 (0.5) | 2.0 (0.3) | 0.8 (0.2) | 0.2 (0.1) | 1.7 (0.2) |
| Yes | 7 | Yes | 1.6 (0.2)7-150 | 0.8 (0.1)7-150 | 0.5 (0.1) | 0.1 (0.0) | 0.6 (0.1)7-151 |
| No | 10 | No | 16.7 (3.0) | 11.7 (2.2) | 4.5 (0.6) | 3.4 (0.4) | 10.1 (2.0) |
| No | 10 | Yes | 8.0 (2.2)7-150 | 4.9 (1.3)7-150 | 2.4 (1.0) | 1.1 (0.6)7-150 | 3.8 (1.0)7-150 |
| Yes | 10 | No | 17.0 (1.5) | 12.2 (1.2) | 3.7 (0.5) | 1.9 (0.2) | 11.4 (1.2) |
| Yes | 10 | Yes | 10.1 (0.6)7-151 | 6.9 (0.6)7-151 | 2.0 (0.2)7-150 | 0.7 (0.2)7-151 | 6.0 (0.8)7-151 |
| No | 14 | No | 29.2 (3.5) | 12.0 (0.9) | 16.6 (2.7) | 17.1 (3.0) | 7.5 (0.4) |
| No | 14 | Yes | 17.7 (0.4)7-150 | 8.3 (1.0)7-150 | 9.1 (1.2)7-150 | 7.6 (2.4)7-150 | 5.3 (1.6) |
| Yes | 14 | No | 36.4 (2.4) | 16.4 (2.4) | 18.9 (1.4) | 17.1 (0.8) | 11.2 (2.0) |
| Yes | 14 | Yes | 22.2 (2.4)7-151 | 10.4 (2.0) | 10.9 (0.6)7-151 | 6.0 (0.4)7-151 | 8.1 (2.0) |
B6-CD45.1 mice were lethally irradiated and administered congenic B6-CD45.2 BM as described in Materials and Methods. On days −1 and +2 continuing twice weekly through day +14 post-BMT, mice were administered irrelevant IgG or αCD48 MoAb (300 μg/dose) IP. Cohorts of mice as indicated were splenectomized 2 weeks before BMT. At the indicated time periods post-BMT, four mice per group were individually analyzed for the absolute number of cells present in the BM. Flow cytometric analysis was performed to determine the absolute number of donor (CD45.2+) or host (CD45.2−) cells, CD19+ B cells, or Mac1+ cells present in each compartment. Values expressed are the mean values × 10−6. The numbers in parenthesis are 1 SEM.
Abbreviation: NE, not evaluable.
P < .05 as compared with irrelevant IgG controls.
P < .01 as compared with irrelevant IgG controls.